Dr. John Ridden has almost 20 years of experience in both large and small BioPharma progressing a number of projects through preclinical research to candidate drug nomination. Following a DPhil in Clinical Biochemistry at Oxford John went on to complete a Postdoctoral position in Peter Parker’s lab at the Institute for Cancer Research working on identifying and characterising a new class of kinases involved in cancer. John then worked for a small biotech company working in oncology and dermatology therapy areas and from here moved to Pfizer for 7 years where he led a number of drug discovery projects in Cardiovascular and Tissue Repair research areas. Subsequently he moved to AstraZeneca where he worked for 11 years at a senior leadership level in target identification and translational research supporting Oncology, Respiratory and Inflammation, and Cardiovascular research areas.
Dr Mike DaviesChief Medical Officer
Mike graduated from Edinburgh University Medical School in 1985 and has over 18 years of Pharma experience in large, medium and small BioPharma in EU and US. Mike worked for 5 years at Pfizer where he led the early clinical development in Tissue Repair and Cardiovascular projects. He then moved to biotech in Manchester Incubator where he again lead the clinical development in anti-scarring and wound healing compounds at Renovo. Mike progressed into consultancy and worked for dermatology companies in US and EU. He also spent 18 months as Medical Director at AstraZeneca. From 2005, Mike worked as Vice President at Shire Pharmaceuticals for 4 years where he lead the late phase development and EU registration of Dynepo™, Fosrenol®, and Lialda™/Mezavant®. For the last 3 years Mike has been Vice President of the Global Strategic Drug Development Unit at Quintiles Transnational where he covers all aspects of preclinical and clinical drug development and scientific/medical portfolio analysis, including portfolio management, regulatory and pharmacogenetics expertise, with a specialist interest in translational medicine.
Dr. David CookChief Scientific Officer
David has a background in biochemistry, immunology and molecular biology with a PhD from Imperial College, London and three years of post-doctoral experience. David has worked in the pharmaceutical industry for AstraZeneca for more than 17 years in a wide variety of R&D roles both in the UK and the US. He initially worked in the respiratory and inflammation area and was responsible for identifying the mode-of-action for a new class of immunosuppressive. David moved into the safety functions six years ago since when he has led a number of global initiatives developing new approaches to improve the understanding of safety in new medicines. David has experience across the drug discovery and development pipeline from target selection to supporting market products and has worked on projects in many disease areas including Respiratory and Inflammation, Infection, Cardiovascular, CNS and Pain and Oncology.
Simon WallworkLegal Counsel
Simon is a corporate lawyer and partner at Weightmans. With over 20 years experience advising on acquisitions, disposals, private equity and public market transactions, commercial agreements and joint ventures for a wide variety of clients including public and private companies, banks, venture capital funds and partnerships. Simon has worked within the Life Sciences sector for most of his career. He has a detailed knowledge of the market and has advised a number of companies from start-up, through funding to eventual sale.